{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T09:06:02Z","timestamp":1772269562475,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T00:00:00Z","timestamp":1546992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1038\/s41417-018-0069-3","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T03:35:57Z","timestamp":1546918557000},"page":"22-29","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prognosis value of RBBP8 expression in plasma cell myeloma"],"prefix":"10.1038","volume":"27","author":[{"given":"Weilong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4448-5399","authenticated-orcid":false,"given":"Xue","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoni","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuozhen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoliang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,9]]},"reference":[{"key":"69_CR1","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMra041875","volume":"351","author":"RA Kyle","year":"2004","unstructured":"Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860\u201373.","journal-title":"N Engl J Med"},{"key":"69_CR2","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1038\/leu.2015.33","volume":"29","author":"LJ Costa","year":"2015","unstructured":"Costa LJ, Gonsalves WI, Kumar SK. Early mortality in multiple myeloma. Leukemia. 2015;29:1616\u20138.","journal-title":"Leukemia"},{"key":"69_CR3","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516\u201320.","journal-title":"Blood"},{"key":"69_CR4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/j.1365-2141.2007.06921.x","volume":"140","author":"M Pineda-Roman","year":"2008","unstructured":"Pineda-Roman M, Zangari M, Haessler J, Anaissie E, Tricot G, van Rhee F, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol. 2008;140:625\u201334.","journal-title":"Br J Haematol"},{"key":"69_CR5","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1056\/NEJMoa053583","volume":"354","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021\u201330.","journal-title":"N Engl J Med"},{"key":"69_CR6","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770\u201381.","journal-title":"N Engl J Med"},{"key":"69_CR7","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1182\/blood-2007-07-101212","volume":"111","author":"A Abdelkefi","year":"2008","unstructured":"Abdelkefi A, Ladeb S, Torjman L, Othman TB, Lakhal A, Romdhane NB, et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is super ior to double autologous transplantation in multiple myeloma: results of a multicenter randomized cl inical trial. Blood. 2008;111:1805\u201310.","journal-title":"Blood"},{"key":"69_CR8","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","volume":"106","author":"PL Bergsagel","year":"2005","unstructured":"Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr, et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106:296\u2013303.","journal-title":"Blood"},{"key":"69_CR9","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020\u20138.","journal-title":"Blood"},{"key":"69_CR10","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1182\/blood-2009-12-261032","volume":"116","author":"A Broyl","year":"2010","unstructured":"Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010;116:2543\u201353.","journal-title":"Blood"},{"key":"69_CR11","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1182\/blood-2006-09-044974","volume":"109","author":"G Mulligan","year":"2007","unstructured":"Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007;109:3177\u201388.","journal-title":"Blood"},{"key":"69_CR12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","volume":"22","author":"D Chauhan","year":"2012","unstructured":"Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R, et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012;22:345\u201358.","journal-title":"Cancer Cell"},{"key":"69_CR13","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1128\/MCB.26.8.3124-3134.2006","volume":"26","author":"F Liu","year":"2006","unstructured":"Liu F, Lee WH. CtIP activates its own and cyclin D1 promoters via the E2F\/RB pathway during G1\/S progression. Mol Cell Biol. 2006;26:3124\u201334.","journal-title":"Mol Cell Biol"},{"key":"69_CR14","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1074\/jbc.M109.062265","volume":"285","author":"KM Ahmed","year":"2010","unstructured":"Ahmed KM, Tsai CY, Lee WH. Derepression of HMGA2 via removal of ZBRK1\/BRCA1\/CtIP complex enhances mammary tumorigenesis. J Biol Chem. 2010;285:4464\u201371.","journal-title":"J Biol Chem"},{"key":"69_CR15","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1128\/MCB.25.9.3535-3542.2005","volume":"25","author":"PL Chen","year":"2005","unstructured":"Chen PL, Liu F, Cai S, Lin X, Li A, Chen Y, et al. Inactivation of CtIP leads to early embryonic lethality mediated by G1 restraint and to tumorigenesis by haploid insufficiency. Mol Cell Biol. 2005;25:3535\u201342.","journal-title":"Mol Cell Biol"},{"key":"69_CR16","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/nature07955","volume":"459","author":"MH Yun","year":"2009","unstructured":"Yun MH, Hiom K. CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle. Nature. 2009;459:460\u20133.","journal-title":"Nature"},{"key":"69_CR17","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/nsmb.2937","volume":"22","author":"OR Davies","year":"2015","unstructured":"Davies OR, Forment JV, Sun M, Belotserkovskaya R, Coates J, Galanty Y, et al. CtIP tetramer assembly is required for DNA-end resection and repair. Nat Struct Mol Biol. 2015;22:150\u20137.","journal-title":"Nat Struct Mol Biol"},{"key":"69_CR18","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.4161\/cc.8.9.8322","volume":"8","author":"B Gu","year":"2009","unstructured":"Gu B, Chen PL. Expression of PCNA-binding domain of CtIP, a motif required for CtIP localization at DNA replication foci, causes DNA damage and activation of DNA damage checkpoint. Cell Cycle. 2009;8:1409\u201320.","journal-title":"Cell Cycle"},{"key":"69_CR19","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1136\/jnnp-2013-307276","volume":"86","author":"PH Kremer","year":"2015","unstructured":"Kremer PH, Koeleman BP, Pawlikowska L, Weinsheimer S, Bendjilali N, Sidney S, et al. Evaluation of genetic risk loci for intracranial aneurysms in sporadic arteriovenous malformations of the brain. J Neurol Neurosurg Psychiatry. 2015;86:524\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"69_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-018-0447-6","volume":"10","author":"J Mijnes","year":"2018","unstructured":"Mijnes J, Veeck J, Gaisa NT, Burghardt E, de Ruijter TC, Gostek S, et al. Promoter methylation of DNA damage repair (DDR) genes in human tumor entities: RBBP8\/CtIP is almost exclusively methylated in bladder cancer. Clin Epigenetics. 2018;10:15.","journal-title":"Clin Epigenetics"},{"key":"69_CR21","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1093\/hmg\/ddp107","volume":"18","author":"L Quaye","year":"2009","unstructured":"Quaye L, Dafou D, Ramus SJ, Song H, Gentry-Maharaj A, Maharaj AG, et al. Functional complementation studies identify candidate genes and common genetic variants associated wi th ovarian cancer survival. Hum Mol Genet. 2009;18:1869\u201378.","journal-title":"Hum Mol Genet"},{"key":"69_CR22","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/cam4.141","volume":"2","author":"I Soria-Bretones","year":"2013","unstructured":"Soria-Bretones I, Saez C, Ruiz-Borrego M, Japon MA, Huertas P. Prognostic value of CtIP\/RBBP8 expression in breast cancer. Cancer Med. 2013;2:774\u201383.","journal-title":"Cancer Med"},{"key":"69_CR23","doi-asserted-by":"crossref","first-page":"7701","DOI":"10.18632\/oncotarget.6715","volume":"7","author":"J Wang","year":"2016","unstructured":"Wang J, Ding Q, Fujimori H, Motegi A, Miki Y, Masutani M. Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhi bitors. Oncotarget. 2016;7:7701\u201314.","journal-title":"Oncotarget"},{"issue":"2","key":"69_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.bbagen.2006.09.025","volume":"1770","author":"Jianmin Xu","year":"2007","unstructured":"Xu J, Lv S, Qin Y, Shu F, Xu Y, Chen J, et al. TRB3 interacts with CtIP and is overexpressed in certain cancers. Biochim Biophys Acta. 2007;1770:273\u20138.","journal-title":"Biochimica et Biophysica Acta (BBA) - General Subjects"},{"key":"69_CR25","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/nbt.1665","volume":"28","author":"L Shi","year":"2010","unstructured":"Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol. 2010;28:827\u201338.","journal-title":"Nat Biotechnol"},{"key":"69_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09378-9","volume":"7","author":"B Miannay","year":"2017","unstructured":"Miannay B, Minvielle S, Roux O, Drouin P, Avet-Loiseau H. Gu\u00a8\u00a6rin-Charbonnel C, et al. Logic programming reveals alteration of key transcription factors in multiple myeloma. Sci Rep. 2017;7:9257.","journal-title":"Sci Rep"},{"key":"69_CR27","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","volume":"128","author":"N Weinhold","year":"2016","unstructured":"Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, et al. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016;128:1735\u201344.","journal-title":"Blood"},{"key":"69_CR28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ccr.2012.12.001","volume":"23","author":"W Zhou","year":"2013","unstructured":"Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W, et al. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with po or prognosis in myeloma and other cancers. Cancer Cell. 2013;23:48\u201362.","journal-title":"Cancer Cell"},{"key":"69_CR29","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1136\/jmg.39.11.785","volume":"39","author":"S Vilkki","year":"2002","unstructured":"Vilkki S, Launonen V, Karhu A, Sistonen P, Vastrik I, Aaltonen LA. Screening for microsatellite instability target genes in colorectal cancers. J Med Genet. 2002;39:785\u20139.","journal-title":"J Med Genet"},{"key":"69_CR30","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1016\/j.ejca.2010.06.116","volume":"46","author":"C Bilbao","year":"2010","unstructured":"Bilbao C, Ram\u00edrez R, Rodr\u00edguez G, Falc\u00f3n O, Le\u00f3n L, D\u00edaz-Chico N, et al. Double strand break repair components are frequent targets of microsatellite instability in endometri al cancer. Eur J Cancer. 2010;46:2821\u20137.","journal-title":"Eur J Cancer"},{"key":"69_CR31","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.","journal-title":"Lancet Oncol"},{"key":"69_CR32","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/leu.2013.247","volume":"28","author":"WJ Chng","year":"2014","unstructured":"Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28:269\u201377.","journal-title":"Leukemia"},{"key":"69_CR33","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/jamaoncol.2015.23","volume":"1","author":"EE Sigurdardottir","year":"2015","unstructured":"Sigurdardottir EE, Turesson I, Lund SH, Lindqvist EK, Mailankody S, Korde N, et al. The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma. JAMA Oncol. 2015;1:168\u201374.","journal-title":"JAMA Oncol"},{"key":"69_CR34","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","volume":"28","author":"J Hillengass","year":"2010","unstructured":"Hillengass J, Fechtner K, Weber MA, B\u00e4uerle T, Ayyaz S, Heiss C, et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with as ymptomatic multiple myeloma. J Clin Oncol. 2010;28:1606\u201310.","journal-title":"J Clin Oncol"},{"key":"69_CR35","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1101\/gad.1431006","volume":"20","author":"X Yu","year":"2006","unstructured":"Yu X, Fu S, Lai M, Baer R, Chen J. BRCA1 ubiquitinates its phosphorylation-dependent binding partner CtIP. Genes Dev. 2006;20:1721\u20136.","journal-title":"Genes Dev"},{"key":"69_CR36","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nature06337","volume":"450","author":"AA Sartori","year":"2007","unstructured":"Sartori AA, Lukas C, Coates J, Mistrik M, Fu S, Bartek J, et al. Human CtIP promotes DNA end resection. Nature. 2007;450:509\u201314.","journal-title":"Nature"},{"key":"69_CR37","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.molcel.2013.03.023","volume":"50","author":"M Steger","year":"2013","unstructured":"Steger M, Murina O, Huhn D, Ferretti LP, Walser R, Hanggi K, et al. Prolyl isomerase PIN1 regulates DNA double-strand break repair by counteracting DNA end resection. Mol Cell. 2013;50:333\u201343.","journal-title":"Mol Cell"},{"key":"69_CR38","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1101\/gr.125567.111","volume":"22","author":"G Ciriello","year":"2012","unstructured":"Ciriello G, Cerami E, Sander C, Schultz N. Mutual exclusivity analysis identifies oncogenic network modules. Genome Res. 2012;22:398\u2013406.","journal-title":"Genome Res"},{"key":"69_CR39","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1084\/jem.20121975","volume":"210","author":"A Bothmer","year":"2013","unstructured":"Bothmer A, Rommel PC, Gazumyan A, Polato F, Reczek CR, Muellenbeck MF, et al. Mechanism of DNA resection during intrachromosomal recombination and immunoglobulin class switching. J Exp Med. 2013;210:115\u201323.","journal-title":"J Exp Med"},{"key":"69_CR40","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1586\/14737140.2014.868776","volume":"14","author":"KC Chan Chung","year":"2014","unstructured":"Chan Chung KC, Tiedemann RE. Getting to the root of the problem: the causes of relapse in multiple myeloma. Expert Rev Anticancer Ther. 2014;14:251\u20134.","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41417-018-0069-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41417-018-0069-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41417-018-0069-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:10:08Z","timestamp":1684617008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-018-0069-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,9]]},"references-count":40,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["69"],"URL":"https:\/\/doi.org\/10.1038\/s41417-018-0069-3","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,9]]},"assertion":[{"value":"30 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}